Globel (Clopidogrel Besilate)

Globel is indicated for several cardiovascular and cerebrovascular conditions where platelet inhibition is required.

• Prevention of atherothrombotic events in patients with acute coronary syndrome.
• Secondary prevention after myocardial infarction to reduce recurrent heart attacks.
• Stroke prevention in individuals with a prior ischemic stroke or transient ischemic attack.
• Management of peripheral arterial disease to lower the risk of limb ischemia.
• Use in combination with aspirin for dual antiplatelet therapy when clinically indicated.

The safety profile of Globel includes both frequent, mild reactions and rare, potentially serious events.

Common

• Minor bruising or bleeding from gums, nose, or cut sites.
• Gastrointestinal discomfort such as nausea, dyspepsia, or abdominal pain.
• Headache or dizziness that resolves without intervention.
• Skin rash or mild itching.
• Increased bruising after minor trauma.
• Fatigue or feeling of weakness.

Serious

• Severe or uncontrolled bleeding, including gastrointestinal or intracranial hemorrhage.
• Thrombocytopenia or a sudden drop in platelet count.
• Allergic reactions such as angioedema, swelling of the face, or difficulty breathing.
• Hepatic dysfunction indicated by jaundice or elevated liver enzymes.
• Acute renal impairment manifested by reduced urine output.

When prescribing Globel, clinicians consider several precautionary factors to ensure safe use in diverse patient populations.

• Assess bleeding risk, especially in patients with a history of ulcers or recent surgery.
• Evaluate liver function, as hepatic impairment may affect drug metabolism.
• Use cautiously in elderly patients due to increased susceptibility to bleeding.
• Monitor renal function in patients with chronic kidney disease.
• Review concomitant use of other antithrombotic or non‑steroidal anti‑inflammatory drugs.
• Consider pregnancy status; the safety profile in pregnancy is not well established.
• Advise patients to report any unusual bruising or prolonged bleeding.

Globel can interact with several medications, altering its antiplatelet effect or increasing bleeding risk.

Avoid

• Strong CYP2C19 inhibitors such as omeprazole, fluconazole, or ticlopidine, which can reduce clopidogrel activation.
• Concurrent use of oral anticoagulants (e.g., warfarin, dabigatran) that markedly increase bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) or high‑dose aspirin that amplify platelet inhibition.

Use with caution

• Proton pump inhibitors with moderate CYP2C19 activity (e.g., pantoprazole) – monitor therapeutic response.
• Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) – may increase bleeding tendency.
• Herbal supplements such as ginkgo biloba, garlic, or ginger – discuss potential additive antiplatelet effects.